Morphotek Investigation in Colorectal Cancer: Research of MORAb-004 (MICRO)

• Status: Completed
• Trial end date: 2013-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate whether therapy with MORAb-004 is effective and safe in the treatment of metastatic, colorectal cancer.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Morphotek

Criteria

Inclusion Criteria:

• Males and females >18 years old

• Diagnosis of metastatic, colorectal cancer

• Significant medical conditions must be well-controlled and stable for at least 30 days prior to the first treatment infusion

• Be willing and able to provide written informed consent

Exclusion Criteria:

• No prior treatment for metastatic colorectal cancer

• Other serious systemic diseases (bacterial or fungal)

• Clinically significant heart disease or an arrhythmia on an ECG within the past 6 months

• Known allergic reaction to monoclonal antibody therapy